The nation of Zimbabwe has declined a substantial US health deal worth $367m (272 million pounds) spanning five years over Washington's insistence on sensitive information.
This rejection came to light after a government memo dated December was disclosed, revealing that President Emmerson Mnangagwa felt the deal was "skewed".
A government spokesperson later clarified that the US was requesting genetic material for scientific study and commercial gain while refused to guarantee the benefits from future treatments.
"We will now turn to the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had furnished more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for continued dialogue to reach a deal agreeable to all parties so the nation's critical HIV programme can be sustained.
Broader Context
Zimbabwe's decision follows a comparable situation in neighbouring Kenya, where a high court halted a related deal with the US following concerns were filed about the security of citizens' medical information.
Since returning to office recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
USAID had managed aid for the American government, but Trump stated its spending was "wasteful" and his government was seeking government-to-government agreements to boost openness and responsibility.
Based on statements, 16 nations in Africa have so far agreed to similar health pacts, constituting more than $18.3bn in committed funds.
Details of the Rejected Agreement
The money for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration would have delivered significant benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving antiretroviral therapy through American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to share its biological resources and data for a long time, with no equivalent guarantee of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that shared data," Mangwana explained.
"In essence, our nation would supply the basic resources for medical research with no assurance that the final treatments would be available to our citizens if a future health crisis arise."
National Interest and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its push of one-on-one health agreements were undermining systems already established via the global organization.
The spokesperson cited its Pandemic Benefit-Sharing scheme designed to deal with future pandemics.
"This mechanism is intended to ensure that when a country provides its samples, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the resources to create them."
The government's concerns regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We welcome ongoing discussions with our American counterparts on how subsequent collaboration might be structured in a manner that honours the sovereignty and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the government's concerns, but urged that talks need to persist given that much of the nation's HIV programmes were funded by foreign aid.
"Where technical issues arise, such as those involving data governance or agreement terms, these can frequently be addressed via detailed discussion and mutually agreed protections," it commented.
The situation highlights the complex debate between receiving crucial international aid and safeguarding local interests in an increasingly data-driven world.